About Zinc finger protein 653
Zinc finger protein 653 (ZNF653) is a protein
from Homo sapiens identified by UniProt accession
Q96CK0, 615 residues long.
MolForge cross-references it against 0 known binders and
3 disease associations.
Target properties
| Protein name | Zinc finger protein 653 |
|---|
| UniProt accession | Q96CK0 |
|---|
| Gene | ZNF653 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 615 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (3)
Diseases linked to this target (Open Targets).
- diastolic blood pressure · score 0.07
- antiphospholipid antibody measurement · score 0.02
- COVID-19 · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q96CK0-F1 | alphafold | PREDICTED | 49.08 | — |
Amino-acid sequence (615 residues)
MAERALEPEA EAEAEAGAGG EAAAEEGAAG RKARGRPRLT ESDRARRRLE SRKKYDVRRV YLGEAHGPWV DLRRRSGWSD AKLAAYLISL ERGQRSGRHG KPWEQVPKKP KRKKRRRRNV NCLKNVVIWY EDHKHRCPYE PHLAELDPTF GLYTTAVWQC EAGHRYFQDL HSPLKPLSDS DPDSDKVGNG LVAGSSDSSS SGSASDSEES PEGQPVKAAA AAAAATPTSP VGSSGLITQE GVHIPFDVHH VESLAEQGTP LCSNPAGNGP EALETVVCVP VPVQVGAGPS ALFENVPQEA LGEVVASCPM PGMVPGSQVI IIAGPGYDAL TAEGIHLNMA AGSGVPGSGL GEEVPCAMME GVAAYTQTEP EGSQPSTMDA TAVAGIETKK EKEDLCLLKK EEKEEPVAPE LATTVPESAE PEAEADGEEL DGSDMSAIIY EIPKEPEKRR RSKRSRVMDA DGLLEMFHCP YEGCSQVYVA LSSFQNHVNL VHRKGKTKVC PHPGCGKKFY LSNHLRRHMI IHSGVREFTC ETCGKSFKRK NHLEVHRRTH TGETPLQCEI CGYQCRQRAS LNWHMKKHTA EVQYNFTCDR CGKRFEKLDS VKFHTLKSHP DHKPT
Explore Zinc finger protein 653 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets